RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- True Weight Loss Is Rare
- What May Be Missing From Quantum Computing - A Quantum Middle Man
- AMVA4NewPhysics Logo
- New GHOST Technology Leaps Out Of The Screen
- Genetic Testing In Kids - The Science Isn't Complicated But The Psychology Is
- Patients With Recurrent Depression Have Smaller Hippocampi
- Radiation Detectors Click By Design
- "Thank you for your words of encouragement. And, I agree that when it comes to weight control, the..."
- "Hi Bill, thanks for your message - I am considering your input. Maybe some more concept and less..."
- "Thanks for the tips - well indeed the internet is a complex place. But I did want some pink and..."
- "Apologizing for a hiatus due to vacations, I am posting today.... Yes Tommaso, how dare you allow..."
- "Tommaso, I understand the message, and I 100% agree that more women in science is always better..."
- Opera is deadly - but The Tarantino influence in modern opera is killing it
- Gene therapy for cystic fibrosis shows encouraging trial results
- Prion trials and tribulations: Finding the right tools and experimental models
- Old World monkey had tiny, complex brain
- Rumors of southern pine deaths have been exaggerated
Books By Writers Here